Stephen J. Freedland, MD, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and discusses the available treatment options and data that influence treatment selection for patients with the disease.
EP. 1: Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer
Stephen J. Freedland, MD, presents the case of a 67-year-old man with metastatic prostate cancer and give his initial impression.
EP. 2: Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Dr Stephen J. Freedland reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.
EP. 3: Factors for Consideration When Selecting Treatments for Patients with mCRPC
Stephen J. Freedland, MD, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case and outlines which factors, including clinical data, inform his treatment decision-making.
EP. 4: The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
EP. 5: Unmet Needs, Future Directions, and Clinical Pearls in mCRPC
Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.
2 Clarke Drive Cranbury, NJ 08512